Karyopharm Therapeutics Inc
Karyopharm Therapeutics (KPTI) is a biopharmaceutical company focused on therapies that modulate nuclear export, most notably selinexor (XPOVIO), an oral selective inhibitor of nuclear export developed for oncology indications. The company combines a marketed oncology agent with an evolving pipeline of clinical programmes in haematologic and solid tumours. Investors should note Karyopharm is a small-cap, catalyst-driven biotech — market capitalisation is about $102.4m — so the share price can be volatile around trial readouts, regulatory decisions and financing news. Key factors to watch are product sales momentum, upcoming clinical and regulatory catalysts, cash runway and potential dilution from fundraising. Upside may come from positive data, label expansion or partnerships; downside risks include trial setbacks, regulatory hurdles and competition. This is general educational information, not personalised advice; biotech investing is high risk and may be suitable only for those who can tolerate significant losses.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Karyopharm's stock with a target price of $5.21, indicating significant growth potential.
Financial Health
Karyopharm is performing well with high revenue, strong profit margins, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring KPTI
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketHematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts or regulatory decisions can move the stock materially; positive results can create upside, though outcomes are uncertain.
Novel mechanism focus
The company’s approach targets nuclear export — a different mechanism in oncology — which may offer differentiated opportunities but also scientific and commercial risk.
Commercial progress watch
Monitor product sales, geographic uptake and partnership activity for signs of commercial traction; small market capitalisation means progress or setbacks can have large effects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
